| Title | Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. | | Author(s) | Weaver TA, Charafeddine AH, Agarwal A, Turner AP, Russell M, Leopardi FV, Kampen RL, Stempora L, Song M, Larsen CP, Kirk AD | | Institution | Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA. | | Source | Nat Med 2009 Jul; 15(7):746-9. | | MeSH | Animals
Antigens, CD2
Blood Transfusion
Graft Survival
Immunoconjugates
Immunologic Memory
Kidney Transplantation
Macaca mulatta
Recombinant Fusion Proteins
Sirolimus
T-Lymphocytes
Transplantation, Homologous
| | Abstract | Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA -3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
| | PubMed ID | 19584865 |
|
